bullish

セルジーンとブリストル・マイヤーズ スクイブ – 過小評価され、過小評価されている

820 Views18 Jan 2019 11:41
Syndicated
製薬およびバイオテクノロジー株にとっての2018年の惨憺たる状況は、はるか昔のことのようです。2019年は、2つの大型取引で華々しく幕を開けました…
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
x